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Abstract
Background: Adipocytes express inflammatory mediators that contribute to the low-level,
chronic inflammation found in obese subjects and have been linked to the onset of cardiovascular
disorders and insulin resistance associated with type 2 diabetes mellitus. A reduction in
inflammatory gene expression in adipocytes would be expected to reverse this low-level,
inflammatory state and improve cardiovascular function and insulin sensitivity. The natural
products, curcumin and resveratrol, are established anti-inflammatory compounds that mediate
their effects by inhibiting activation of NF-κB signaling. In the present study, we examined if these
natural products can inhibit NF-κB activation in adipocytes and in doing so reduce cytokine
expression.
Methods: Cytokine (TNF-α, IL-1β, IL-6) and COX-2 gene expression in 3T3-L1-derived
adipocytes was measured by quantitative real-time PCR (qRT-PCR) with or without TNFα-
stimulation. Cytokine protein and prostaglandin E2 (PGE2) expression were measured by ELISA.
Effects of curcumin and resveratrol were evaluated by treating TNFα-stimulated adipocytes with
each compound and 1) assessing the activation state of the NF-κB signaling pathway and 2)
measuring inflammatory gene expression by qRT-PCR and ELISA.
Results: Both preadipocytes and differentiated adipocytes express the genes for TNF-α, IL-6, and
COX-2, key mediators of the inflammatory response. Preadipocytes were also found to express
IL-1β; however, IL-1β expression was absent in differentiated adipocytes. TNF-α treatment
activated NF-κB signaling in differentiated adipocytes by inducing IκB degradation and NF-κB
translocation to the nucleus, and as a result increased IL-6 (6-fold) and COX-2 (2.5-fold) mRNA
levels. TNF-α also activated IL-1β gene expression in differentiated adipocytes, but had no effect
on endogenous TNF-α mRNA levels. No detectable TNFα or IL-1β was secreted by adipocytes.
Curcumin and resveratrol treatment inhibited NF-κB activation and resulted in a reduction of TNF-
α, IL-1β, IL-6, and COX-2 gene expression (IC50 = 2 μM) and a reduction of secreted IL-6 and PGE2
(IC50 ~ 20 μM).
Conclusion: Curcumin and resveratrol are able to inhibit TNFα-activated NF-κB signaling in
adipocytes and as a result significantly reduce cytokine expression. These data suggest that
curcumin and resveratrol may provide a novel and safe approach to reduce or inhibit the chronic
inflammatory properties of adipose tissue.
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Obesity is now known to play a causal role in the complex
disease state of metabolic syndrome, as well as being a sig-
nificant risk factor for cardiovascular disorders and diabe-
tes [1,2]. Although once thought to serve as a simple
storage depot for excess fats, adipose tissue also regulates
organismic metabolism through a variety of signaling
mechanisms including autonomic nervous stimulation
and secreted hormones [3,4]. When in proper balance,
these regulatory mechanisms effectively control energy
preservation (lipogenesis) during the post-prandial
period and energy mobilization (lipolysis) during times
of increased energy expenditure.
In addition to these mechanisms of metabolic regulation,
adipose tissue is also capable of producing proteins that
are classical mediators of the inflammatory response. In
the early 1990's, it was discovered that adipocytes synthe-
size and secrete the pro-inflammatory cytokine, Tumor
Necrosis Factor-alpha (TNF-α) [5]. Since then, it has been
shown that a number of acute phase reactants and inflam-
matory mediators are made by adipocytes including plas-
minogen activator inhibitor-1, IL-1β, IL-6, IL-8, IL-10, IL-
15, hepatocyte growth/scatter factor and prostaglandin E2
(PGE2) [6]. In fact, enough of these factors are secreted by
adipocytes that overall systemic levels are significantly ele-
vated in obese subjects [7] and a number of studies have
now identified a direct correlation between body mass
index (BMI) and systemic levels of inflammatory proteins
[8]. These clinical observations provide key evidence link-
ing obesity with cardiovascular disorders and begin to
shed light on how low-level, chronic inflammation
adversely affects cardiovascular function in obese subjects.
Recent evidence suggests that cytokine expression in adi-
pose tissue is initiated by crosstalk occurring between adi-
pocytes and macrophages [8-11]. Macrophages typically
account for 5–10% of cells within adipose tissue obtained
from non-obese donors; however, in diet-induced obes-
ity, macrophage infiltration can account for up to 60% of
all cells in adipose tissue [12]. Cytokines secreted by mac-
rophages, including TNFα, IL-1β and IL-6, are known to
stimulate cytokine expression in adipocytes [13-15] and
establish a paracrine loop between these two cell types
[16]. This paracrine stimulation in turn elevates systemic
cytokine levels observed in obese individuals. In bone fide
inflammatory cells, cytokine gene expression is activated
following activation of the Nuclear Factor-kappaB (NF-
κB) signal transduction pathway [17]. Activation of the
NF-κB pathway is mediated by a variety of signals includ-
ing those initiated from the TNFα receptor and Toll-like
receptor family. NF-κB itself is a heterodimeric transcrip-
tion factor that is retained in the cytosol in its inactive
state by complexing with a set of inhibitory proteins des-
ignated IκB. Upon receptor activation of NF-κB signaling
the IκB complex is phosphorylated by IκB kinase (IKK).
This in turn leads to its dissociation from NF-κB and rapid
degradation by the proteosome. Free NF-κB is then able to
translocate to the nucleus where it binds to specific pro-
moter elements resulting in the activation of a battery of
genes, including those encoding for inflammatory pro-
teins.
In adipocytes, both expression and activity of NF-κB
increase during differentiation [18] suggesting that it is a
key player in mediating adipose-specific cytokine expres-
sion. Moreover, excessive NF-κB activity has been associ-
ated with the development of type 2 diabetes as obese
individuals have high circulating levels of TNF-α, IL-1β
and IL-6 that, like cardiovascular risk, directly correlate
with insulin resistance [7,19,20]. Collectively, these
observations suggest that therapeutic targeting of the NF-
κB signaling pathway in adipose tissue represents a logical
pursuit to reduce systemic cytokine levels and reverse their
negative influence on cardiovascular function and dia-
betic progression.
There are no shortages of reported inhibitors of NF-κB
activation as they now number in the hundreds [21].
Unfortunately, the targets for many of these inhibitors are
not necessarily restricted to the NF-κB pathway raising
concerns of potential side effects due to off-target inhibi-
tion. As an alternative, we have investigated the effective-
ness of certain natural products to inhibit the NF-κB
signaling pathway [22]. Many natural products have been
shown to possess low level toxicity and potent anti-
inflammatory properties by targeting similar pathways as
non-steroidal anti-inflammatory drugs (NSAIDs). Two
natural polyphenols of particular interest are curcumin
and resveratrol. These natural products are modest inhib-
itors of NF-κB activation and inflammatory gene expres-
sion [22-30] and have proven safe in human clinical trials
[31-33]. In the present study, we examined if curcumin
and resveratrol are also able to inhibit NF-κB activation in
adipocytes and in doing so inhibit cytokine expression in
these cells. We believe that using natural products to
inhibit the chronic inflammatory response of adipose tis-
sue may provide a novel approach to reduce systemic
cytokine levels which in turn is expected to improve cardi-
ovascular health and insulin sensitivity.
Methods
Reagents
TNFα was obtained by R&D Systems, Minneapolis, MN
and was used in all experiments at a final concentration of
20 ng/ml. Lipopolysaccharide (LPS) was purchased from
Sigma, St. Louis, MO and used to activate BV-2 murine
macrophages at a final concentration of 20 μg/ml. Curcu-
min was synthesized in the lab [34] and resveratrol was
purchased from A.G. Scientific Inc., San Diego, CA.Page 2 of 13
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For our studies, we utilize an in vitro cell culture system
that has been extensively characterized for adipocyte dif-
ferentiation, namely mouse 3T3-L1 fibroblasts [35]. Fol-
lowing induction into the differentiation pathway, 3T3-L1
cells undergo growth arrest, become spherical, and form
large intracellular lipid droplets. Subcutaneous implanta-
tion of these cells in mice results in tissue masses that are
histologically indistinguishable from white adipose tissue
[36,37]. 3T3-L1 cells were obtained from American Type
Culture Collection (Manassas, VA) and grown in Dul-
becco's modified Eagle's medium (DMEM) (Invitrogen,
Carlsbad, CA) supplemented with 10% (v/v) fetal calf
serum (Irvine Scientific, Santa Ana, CA), 1 mM sodium
pyruvate, 0.1 mM non-essential amino acids, 2 mM L-
glutamine, 100 μg/ml streptomycin sulfate, and 100
units/ml penicillin. Cells were cultured at 37°C with 10%
CO2 and passaged twice weekly. To differentiate 3T3-L1
cells into adipocytes, cells were incubated with 250 nM
dexamethasone, 450 μM 3-isobutyl-1-methylxanthine,
and 167 nM insulin for 2 days, followed by 167 nM insu-
lin for an additional 3 days.
BV-2 murine macrophages (a gift from Dr. Paul Stemmer,
Wayne State University, Detroit, MI) were grown in RPMI-
1640 (Hyclone®, Logan, UT) supplemented with 10% (v/
v) fetal calf serum, 1 mM sodium pyruvate, 2 mM L-
glutamine, 100 μg/ml streptomycin sulfate, and 100
units/ml penicillin. Cells were cultured at 37°C with 5%
CO2 and passaged twice weekly.
qRT-PCR and RT-PCR analysis
Total RNA was purified from cells using RNeasy (Qiagen,
Valencia, CA) and converted to cDNA using TaqMan®
Reverse Transcriptase (Applied Biosystems, Branchburg,
NJ). Cyclooxygenase-2 (COX-2), IL-1β, IL-6, TNFα, and β-
actin expression levels were measured by quantitative
Real-Time PCR analysis (qRT-PCR) of cDNA samples.
Gene and primer information can be found in Table 1.
Amplification of leptin and macrophage specific markers
F4/80 and Mac-1 was performed by reverse transciptase-
PCR (RT-PCR).
qRT-PCR was performed using ABsolute QPCR SYBR
Green Mix (Fisher Scientific, Atlanta, GA) with the follow-
ing cycling parameters: 1 cycle, 95°C, 15 min; 40 cycles,
95°C, 15 sec, 63°C, 1 min. Changes in gene expression
were determined by the Comparative CT method. Since β-
actin gene expression is unaffected by TNFα treatment, β-
actin mRNA levels were quantified in each sample using
identical cycling conditions and used to normalize values
obtained for COX-2, IL-1β, IL-6, and TNFα expression.
Amplified products were separated on 3% agarose gels
and stained with Gel Star® (Cambrex, Rockland, ME).
Immunoblotting
Cell lysates were prepared using 1× Laemmli sample
buffer (Sigma-Aldrich). After heating samples at 95°C for
10 min, they were vortexed on high for 20 s to shear DNA
and reduce viscosity. Proteins were then separated by SDS-
PAGE and transferred to PVDF membrane (0.2 μm, Bio-
Rad, Hercules, CA) using a wet tank transfer system (Bio-
Rad). Membranes were blocked with 20 mM Tris, pH 7.4,
150 mM NaCl (TBS) containing 0.1% (v/v) Tween-20, 5%
(v/v) calf serum for 30 minutes at 23°C and incubated
with either anti-IκB monoclonal antibody (2 μg/ml,
Imgenex, San Diego, CA) or anti-β-actin monoclonal anti-
body (1:500, no. A-4700, Sigma-Aldrich) for 24 h at
23°C. Membranes were washed three times (10 min each)
with TBS, 0.1% (v/v) Tween-20, and bound antibodies
were detected with goat anti-mouse HRP-conjugated sec-
ondary antibody (1:3000, BioRad) followed by chemilu-
Table 1: Gene and primer information used in this study.
Gene GenBank no. 5' primer – top sequence
3' primer – bottom sequence
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according to the manufacturer's instructions (Millipore,
Billerica, MA). Images were captured using a Syngene
GeneGnome system equipped with a Peltier-cooled 16-bit
CCD camera and saturation detection. Densitometry was
performed using ImageJ software (version 1.37; National
Institutes of Health, http://rsb.info.nih.gov/ij/).
NF-κB nuclear localization assay
BV-2 murine macrophages were cultured in the absence or
presence of LPS (20 μg/ml) for 24 h. 3T3-L1-derived adi-
pocytes were cultured in the absence or presence of TNFα
(20 ng/ml) or incubated with TNFα together with curcu-
min or resveratrol or vehicle alone (dimethylsulfoxide at
0.1% final concentration) for 62 h. Nuclear localized NF-
κB was quantified using a Transcription Factor ELISA Kit
to detect activated p65 subunit of NF-κB (Panomics, Fre-
mont, CA). All reagents required for preparing nuclear
extracts and performing ELISA assays were included and
their use was described by the manufacturer.
Cytotoxicity assay
Cells were grown in 96-well plates to 80–90% confluency.
Media was replaced with fresh complete media containing
the indicated concentrations of curcumin or resveratrol,
or vehicle alone (dimethylsulfoxide at 0.1% final concen-
tration). After a 24 h incubation, WST-1 (Roche Molecular
Biochemicals, Indianapolis, IN) was added to the cultures
to a final concentration of 10% (vol/vol). Following an
additional incubation at 37°C for 60 min, absorbance
was recorded for each well (450 nm; reference wave-
length, 690 nm).
Cytokine and PGE2 ELISA
Quantitation of cytokine protein levels from cell culture
supernatants was done by ELISA Ready-SET-Go! kit (eBio-
science, San Diego, CA) per manufacturer's instructions.
Parameter™ PGE2 competitive binding ELISA kit (R&D
systems, Minneapolis, MN) was used to measure PGE2
levels.
Statistical analyses
All experimental protocols were done in at least triplicate
points and error bars represent standard deviations of
mean values. Student's t-test was performed on some fig-
ures using data sets composed of a minimum of triplicate
values. Comparison of data sets resulting in p values <
0.05 were considered statistically significant.
Results
Cytokine expression profile in 3T3-L1 preadipocytes and 
differentiated adipocytes
Immunocytochemical analysis has shown that preadi-
pocytes often express macrophage specific antigens [38]
suggesting that preadipocytes are derived from a mono-
cytic cell lineage. Because our studies are focused on
cytokine expression by adipocytes, we first needed to con-
firm that our mature, fully differentiated 3T3-L1-derived
adipocytes have not undergone conversion to a macro-
phage line. We addressed this need by determining if our
cultured adipocytes express the macrophage-specific
markers, Mac-1 and F4/80. Rather than assessing if these
markers are expressed by the more common method of
flow cytometry, we chose to test for expression by per-
forming the more sensitive reverse transcriptase-PCR anal-
ysis. As expected, both markers were expressed in our
positive control cell line, BV-2 murine macrophages (Fig.
1A). By contrast, no expression could be detected in our
3T3-L1-derived adipocytes, confirming that differentiat-
ing 3T3-L1 cells does not result in conversion to a macro-
phage-like phenotype.
With this criteria met, we next examined the cytokine
expression profile of 3T3-L1 preadipocytes as well as
cytokine expression after differentiation to adipocytes.
Specifically, we assessed TNFα, IL-1β, IL-6, and COX-2
expression using RT-PCR analysis. We included COX-2 in
our list of inflammatory genes to examine since its expres-
sion, like the other inflammatory mediators, has also
been associated with obesity [39]. As shown in Figure 1B,
both 3T3-L1 preadipocytes and differentiated adipocytes
express several key mediators of the inflammatory
response: TNFα, IL-6, and COX-2. Notably, preadipocytes
were found to express IL-1β; however, IL-1β expression
was absent in fully differentiated adipocytes.
TNFα treatment activates IL-1β expression in 
differentiated adipocytes and increases expression of IL-6 
and COX-2
Infiltrating macrophages are the major source of TNFα
within adipose tissue [6]. Since TNFα is thought to initiate
the paracrine crosstalk between macrophages and adi-
pocytes [9,16,40], we examined if TNFα stimulation is
able to alter TNFα, IL-1β, IL-6, and COX-2 gene expres-
sion in differentiated adipocytes. Differentiated adi-
pocytes were incubated with TNFα and target gene
expression was measured by qRT-PCR. We found that
TNFα treatment of differentiated adipocytes did indeed
increase IL-6 and COX-2 expression in a time dependent
manner (Fig. 2). After 62 h of TNFα incubation, IL-6 gene
expression was elevated by 6-fold and COX-2 expression
was increased by 2.5-fold. Moreover, TNFα treatment also
activated IL-1β gene expression in adipocytes and
increased its levels by ~2-fold after 62 h treatment. TNFα
treatment had no measurable effect on TNFα gene expres-
sion in differentiated adipocytes (data not shown).
Activation of NF-κB in adipocytes
To further examine the NF-κB signaling pathway in adi-
pocytes, we investigated the immediate upstream eventsPage 4 of 13
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tion to the nucleus. Activation of NF-κB in inflammatory
cells, and in many other cell types, is known to require its
dissociation from its inhibitory subunit, IκB. This dissoci-
ation occurs following phosphorylation of IκB and subse-
quent IκB degradation by the proteosome. To determine
if this same activation sequence occurs in adipocytes, we
incubated cells with TNFα and examined if IκB is
degraded as a result of this stimulus. In the absence of
TNFα, no evidence of IκB degradation was found in adi-
pocytes (Fig. 3). With TNFα treatment, we found that IκB
was rapidly degraded within 15 minutes and reappeared
after 60 minutes. This time course is similar to that found
for inflammatory cells [41], suggesting that the upstream
signaling events responsible for IκB phosphorylation and
degradation are comparable between inflammatory cells
and adipocytes.
We also examined the effect of TNFα treatment on the
activation state of NF-κB in adipocytes. Since NF-κB acti-
vation is accompanied by its translocation to the nucleus,
we compared levels of NF-κB found in nuclear extracts
from TNFα-treated and untreated cells. Using a commer-
cially available ELISA, we found, as expected, lipopolysac-
charide (LPS) treatment of murine macrophages induced
the translocation of NF-κB into the nucleus (Fig. 4). Inter-
estingly, untreated adipocytes demonstrate some NF-κB
in nuclear extracts. TNFα-stimulation increased the
amount of NF-κB translocation by ~2-fold, which corrob-
orates data presented in Figure 3 showing TNFα-mediated
IκB degradation.
TNFα treatment increases expression of IL-1β, IL-6 and COX-2 xpressio  in differ ntiated adipocytesFigure 2
TNFα treatment increases expression of IL-1β, IL-6 
and COX-2 expression in differentiated adipocytes. 
3T3-L1 preadipocytes were differentiated into adipocytes as 
in Fig. 1. Following differentiation, cells were incubated with 
TNFα for the indicated times. Total RNA was extracted and 
gene expression levels were measured by qRT-PCR using the 
Comparative CT method. Amplification of β-actin sequence 
was performed in parallel and used to normalize values 
obtained for target genes. Expression levels for IL-6 and 
COX-2 were determined by comparing values obtained at 
each time point following TNFα stimulation to values 
obtained from untreated cells. Expression of these genes in 
untreated adipocytes was assigned a value of 1 to determine 
fold-changes in expression due to TNFα stimulation. Expres-
sion of IL-1β resulting from TNFα stimulation was assessed 
by comparing later time points (20 and 62 h) to 10 h TNFα 
treatment time since no IL-1β expression could be measured 
in untreated adipocytes. For this analysis, IL-1β expression 
measured at 10 h post-TNFα treatment was assigned a value 
of 1 to determine fold-changes in expression at later time 
points.
Cytokine and COX-2 expression profile in 3T3-L1 preadi-pocytes and differentiated adip cytesFigure 1
Cytokine and COX-2 expression profile in 3T3-L1 
preadipocytes and differentiated adipocytes. (A) 3T3-
L1 cells were incubated with adipocyte differentiation rea-
gents (250 nM dexamethasone, 450 μM 3-isobutyl-1-methyl-
xanthine, and 167 nM insulin) for two days followed by 
incubation with insulin (167 nM) for an additional three days. 
Total RNA was extracted from 3T3-L1-derived adipocytes 
and BV-2 murine macrophages, converted to cDNA and sub-
jected to PCR analysis using primers specific for Mac-1 and 
F4/80. β-actin amplification was performed in parallel as a 
loading control. (B) 3T3-L1 cells were cultured without 
(preadipocytes) or with (adipocytes) differentiation reagents 
as described for (A). Total RNA was extracted from cells and 
processed for PCR analysis using primers for the indicated 
genes. Amplification of leptin sequence confirmed differentia-
tion of preadipocytes.Page 5 of 13
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adipocytes
An important consideration in our exploration of the
therapeutic effects of curcumin and resveratrol is their low
level cytotoxicities. In the drug development pipeline,
many synthetic compounds fail early in the evaluation
process because of high cytotoxic levels. Prior to examin-
ing if curcumin and resveratrol have an effect on cytokine
production by adipocytes, we wish to confirm that these
natural products are not harmful to this cell type.
Although many previous studies have shown that these
compounds are not cytotoxic at their effective doses, no
data is available regarding their effect on adipocyte cell
health. To address this issue, we incubated adipocytes
with various concentrations of curcumin or resveratrol
and quantified the metabolic state of cells as a measure of
their viability. Consistent with data obtained for other cell
types, curcumin and resveratrol demonstrate cytotoxicity
only at relatively high concentrations. Extrapolation of
the data shown in Figure 5 reveals LD50 values of 70 and
220 μM for curcumin and resveratrol, respectively.
Curcumin and resveratrol inhibit IκB degradation and NF-
κB translocation to the nucleus in adipocytes
Inhibition of NF-κB activation by curcumin and resvera-
trol has been demonstrated in many cell types [27,42,43];
however, the effect of these natural products on NF-κB
activation and cytokine production in adipocytes has not
been examined. To determine if these natural products
might be useful compounds in limiting NF-κB activation
in adipocytes, we incubated cells with TNFα in the
absence or presence of 20 μM curcumin or resveratrol and
examined the effect of this treatment on IκB degradation
and NF-κB translocation to the nucleus. Consistent with
our results shown in Figures 3 and 4, TNFα treatment
alone resulted in degradation of IκB (Fig. 6A and 6B) and
increase levels of NF-κB in nuclear extracts (Fig. 6C).
When cells were co-incubated with TNFα and either cur-
cumin or resveratrol, degradation of IκB was inhibited, as
was NF-κB nuclear translocation, indicating that these
compounds are effective inhibitors of NF-κB activation in
adipocytes.
Curcumin and resveratrol reduce cytokine and COX-2 
gene expression in adipocytes
Based on these observations, we next asked if these natu-
ral products were also capable of inhibiting cytokine and
COX-2 gene expression in adipocytes, thereby establish-
ing their potential as therapeutics to counter the inflam-
matory response of adipose tissue. Toward this goal, we
activated the NF-κB pathway in adipocytes with TNFα and
incubated cells with vehicle alone or varying concentra-
tions of curcumin or resveratrol for 62 h followed by
quantification of TNFα, IL-1β, IL-6, and COX-2 gene
expression by qRT-PCR analysis. We found that both cur-
cumin (Fig. 7) and resveratrol (Fig. 8) were able to reduce
expression of all four genes in a dose-dependent manner.
IC50 values were estimated to be < 2 μM for inhibition of
COX-2, IL-1β and IL-6 gene expression, and ~8 μM for
inhibition of TNFα gene expression.
Secreted cytokine protein and PGE2 levels are reduced by 
curcumin and resveratrol
To extend our observations defining the effects of curcu-
min and resveratrol on expression of inflammatory medi-
ators by adipocytes, we next performed ELISA-based
assays to quantify their impact on secreted levels of
cytokine protein and PGE2. PGE2 levels were measured
since its synthesis is mediated by COX-2 and is therefore
a direct reflection of COX-2 protein expression. To our
surprise, we were unable to detect any TNFα or IL-1β
secreted by adipocytes in spite of the presence of measur-
able gene expression levels (data not shown). Conversely,
TNFα treatment of adipocytes significantly elevated
secreted levels of IL-6 (Fig. 9) and PGE2 (Fig. 10). By incu-
bating adipocytes with TNFα together with either curcu-
min or resveratrol, we were able to measure a dose-
dependent reduction in secreted levels of IL-6 (Fig. 9) and
PGE2 (Fig. 10).
TNFα treatment promotes degradation of IκB in adipocytesFigure 3
TNFα treatment promotes degradation of IκB in adi-
pocytes. (A) Adipocytes were incubated without (left pan-
els) or with (right panels) TNFα for the indicated times. 
Total cellular proteins were solubilized and subject to immu-
noblot analysis using anti-IκB monoclonal antibody (upper 
panels). Samples were also immunoblotted with anti-β-actin 
monoclonal antibodies in parallel as a loading control (lower 
panels). (B) Densitometric quantitation of IκB shown in (A).Page 6 of 13
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Increased adiposity is now a well established risk factor
for developing complications related to metabolic syn-
drome and type II diabetes mellitus. Mounting evidence
indicates that low level, chronic inflammation resulting
from cytokines secreted by adipose tissue may play a sig-
nificant role in causing, or at the very least aggravating, the
inflammatory component of cardiovascular disease and
in desensitizing cells to insulin leading to high circulating
glucose levels. These observations suggest a hypothesis
that reducing or preventing the inflammatory properties
of adipose tissue represents a novel and promising thera-
peutic approach to curb the progression of cardiovascular
disease and to restore insulin sensitivity in type II diabet-
ics.
Macrophage infiltration has recently been postulated to
be a primary stimulus for fueling the inflammatory prop-
erties of adipose tissue [44]. Monocyte chemoattractants
[9,11], such as monocyte chemoattractant protein-1
(MCP-1) which is synthesized and secreted by adipocytes
[45], are thought to mediate macrophage infiltration and
intensify macrophage expression of TNFα [8]. TNFα has
pleiotropic effects on adipocyte physiology including an
induction of lipolysis to increase the mobilization of free
fatty acids [46,47], activating cytokine expression [8] and
promoting insulin resistance [5,48]. Observations such as
these provide sufficient evidence suggesting that TNFα is
the predominant factor that mediates the crosstalk
between macrophages and adipocytes and that elevated
TNFα levels found in obese individuals establishes a para-
crine loop in adipose tissue [16] that is responsible for the
elevated systemic levels of cytokines seen in obesity.
TNFα mediates its affects on adipocytes by activating the
NF-κB signaling pathway [11,18]; a signaling event that
has been studied extensively in the innate immune
response. In conventional immune cells, activation of the
NF-κB signaling pathway requires relocation of the NF-κB
heterodimer from the cytoplasm to the nucleus where it
functions as part of a multi-protein transcription complex
controlling the expression of most inflammatory media-
tors. In adipose tissue, low level NF-κB activation has
been identified in vivo [49] suggesting that, like in con-
ventional immune cells, NF-κB is largely responsible for
cytokine gene expression in adipocytes. Only recently has
the role of NF-κB in adipose function come under scru-
tiny. Berg, et al., examined NF-κB expression and activity
during adipocyte differentiation and found both parame-
ters to be elevated in fully differentiated adipocytes [18].
Consistent with their findings, we were able to activate
NF-κB signaling in differentiated adipocytes with TNFα
treatment and in doing so demonstrate an increase in NF-
Curcumin and resveratrol show cytotoxicity in adipocytes only at relatively high concentrationsFigure 5
Curcumin and resveratrol show cytotoxicity in adi-
pocytes only at relatively high concentrations. Adi-
pocytes were cultured without or with the indicated 
concentrations of curcumin (l) or resveratrol (m) in com-
plete media containing 10% fetal bovine serum for 24 h. Wst-
1 reagent was then added to cultures to a final dilution of 
1:10, cultures were incubated for an additional one hour and 
color was measured by spectroscopy (450 nm; reference 
wavelength, 690 nm).
TNFα treatment increases NF-κB translocation to the nucleus in adipocytesFigure 4
TNFα treatment increases NF-κB translocation to 
the nucleus in adipocytes. BV-2 murine macrophages or 
adipocytes were incubated without or with LPS or TNFα for 
24 h and 62 h, respectively. Nuclear extracts were prepared 
and NF-κB levels were quantified by ELISA analysis using a 
commercially available system. Student's t-test was per-
formed to determine statistical probability (p).Page 7 of 13
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vations we also examined the upstream signaling event
that is directly responsible for NF-κB activation, namely
IκB degradation. We found that IκB was rapidly degraded
in adipocytes following TNFα treatment and with kinetics
similar to those measured for true immune cells [41].
These data provide compelling evidence that NF-κB sign-
aling in adipocytes shares a similar time course of activa-
tion as inflammatory cells.
Because the NF-κB signaling pathway is such a pleiotropic
pro-inflammatory and pro-survival factor in a wide range
of disorders, it has been an attractive target for small-mol-
ecule inhibitor development. Thus far almost 800 com-
pounds have been reported to inhibit NF-κB activation
[21]. A large fraction of these inhibitors include natural
products that are capable of targeting multiple check-
points in the NF-κB activation pathway. Of particular
interest are the polyphenolic natural compounds, curcu-
min and resveratrol. Curcumin is derived from the spice
turmeric, which comes from the root of Curcuma longa of
the ginger family. It is an established inhibitor of NF-κB
activation [29] and has recently been shown to specifically
target IKK [24]. Inhibitors targeting IKK have so far proven
to be the most effective compounds for preventing the
activation of NF-κB [50-54] by directly preventing the
phosphorylation of IκB, and as a consequence, block NF-
κB translocation to the nucleus. Important for clinical
drug development, curcumin has also been found safe in
six human trials at oral doses up to 8 g/day administered
for 3 months [31,32]. The other natural product that has
been a focus of our laboratory is resveratrol [22]. A prod-
uct of red grapes, resveratrol possesses multiple biological
activities including anti-oxidant and anti-cancer activities,
and like curcumin, is an inhibitor of NF-κB activation [55]
through targeted inhibition of IKK [56]. In addition,
although the extent of its bioavailability is still under
investigation [57,58], resveratrol has been shown to be
quite safe in preclinical trials [33]. In the present study, we
examined if curcumin and resveratrol might represent
promising therapeutics to combat the chronic inflamma-
tory properties of adipose tissue by exploring their effects
on NF-κB activation and inflammatory cytokine expres-
sion in adipocytes. We first identified that curcumin and
resveratrol are able to inhibit NF-κB translocation to the
nucleus in TNFα-stimulated adipocytes. Moreover, we
also found that both natural products are able to prevent
IκB degradation. These data establish that curcumin and
Curcumin and resveratrol prevent IκB degradation and reduce NF-κB nuclear translocation in adipocytesFigure 6
Curcumin and resveratrol prevent IκB degradation and reduce NF-κB nuclear translocation in adipocytes. (A) 
Adipocytes were incubated without or with TNFα for 20 min. In parallel, cells were also treated with TNFα and co-incubated 
with curcumin or resveratrol at the indicated concentrations. Total cellular proteins were solubilized and processed for immu-
noblot analysis using anti-IκB monoclonal antibody (upper panel) or with anti-β-actin monoclonal antibodies (lower panel). (B) 
Densitometric quantitation of IκB shown in (A). (C) Adipocytes were incubated without or with TNFα for 62 h. In parallel, 
cells were also treated with TNFα and co-incubated with curcumin or resveratrol. Nuclear extracts were prepared and NF-κB 
levels were quantified by ELISA analysis as in Fig. 4.Page 8 of 13
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level of IκB phosphorylation by IKK or upstream from this
checkpoint in the NF-κB activation pathway. We next
examined the effects of curcumin and resveratrol on
downstream gene regulation in adipocytes since NF-κB
activation is largely responsible for mediating inflamma-
tory gene expression in immune cells. Indeed, treatment
of TNFα-stimulated adipocytes with curcumin or resvera-
trol resulted in a significant reduction in TNFα, IL-1β, IL-
6, and COX-2 gene expression. The IC50 values measured
for inhibition of IL-1β, IL-6, and COX-2 gene expression
by either compound were found to be < 2 μM; for TNFα
gene expression, the IC50 value was ~8 μM.
During the course of identifying inhibitors for NF-κB sig-
naling, many studies will limit their analysis to measuring
the effects of inhibitors on the transcriptional status of
cytokine genes. Although these studies provide a wealth of
data regarding the direct control of cytokine gene expres-
sion by the state of NF-κB activity, they fall short of iden-
tifying additional mechanisms of regulation at post-
transcriptional levels. Limiting inhibitor identification to
effects on transcriptional levels in bona fide immune cells
may be acceptable since the NF-κB signaling pathway that
mediates these immunological responses has been well
studied [59]. However, because much less is known about
potential multi-level regulatory elements in non-immune
Curcumin reduces TNFα, IL-1β, IL-6, COX-2 gene expression in differentiated adipocytesFigure 7
Curcumin reduces TNFα, IL-1β, IL-6, COX-2 gene expression in differentiated adipocytes. For IL-1β, IL-6, and 
COX-2 expression analysis, differentiated adipocytes were incubated with TNFα and the indicated concentrations of curcumin 
for 62 h. Total RNA was extracted and gene expression levels were measured by qRT-PCR using the Comparative CT method. 
For TNFα expression analysis, differentiated adipocytes were incubated with curcumin in the absence of TNFα stimulation 
since we found that this stimulus has no effect on TNFα expression by adipocytes. For IL-1β, IL-6, and COX-2, relative expres-
sion levels were determined by comparing values obtained from TNFα-stimulated, curcumin-treated adipocytes to TNFα-stim-
ulated, untreated adipocytes (assigned as 100% mRNA expression). Relative expression levels of TNFα were determined by 
comparing values obtained from curcumin-treated adipocytes to untreated adipocytes (assigned as 100% mRNA expression).Page 9 of 13
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analyses should include a quantitative assessment of
secreted cytokines to identify possible post-transcriptional
control of cytokine expression. By extending our analysis
to measuring levels of secreted cytokines, we have identi-
fied unique expression patterns that may have significant
impact on our understanding of adipocyte contributions
to systemic inflammation. First, although adipocytes
express TNFα mRNA, we were unable to measure any
secreted TNFα by ELISA. This observation suggests that
the major source of circulating TNFα found in obese sub-
jects arises from adipose-infiltrating macrophages rather
than adipocytes. A similar observation was made by Fain
and colleagues when comparing isolated adipocytes to
stromal vascular cells obtained from human adipose
explants [6]. In this study the authors found significant
amounts of TNFα secreted by stromal vascular cells, with
little or no detectable TNFα secreted by adipocytes. One
caveat of this study stems from the fact that the adipocytes
were removed from the in vivo environment where they
are exposed to macrophage-derived TNFα. Removal of
TNFα-stimulation from the isolated adipocytes would dis-
continue signaling events that arguably might be neces-
sary to sustain TNFα secretion by adipocytes. Our study
clearly addresses this concern by demonstrating the lack
of TNFα secretion in TNFα-stimulated adipocytes.
We also found that preadipocytes express the gene for IL-
1β, yet differentiated adipocytes show no mRNA expres-
sion. Interestingly, TNFα treatment was able to re-activate
IL-1β mRNA expression in differentiated adipocytes; how-
ever, in spite of this re-activation we were unable to detect
any secreted IL-1β from treated adipocytes indicating that
post-transcriptional mechanisms are in place to prevent
expression of IL-1β protein. These observations may be
interpreted based on the effects of long-term treatment of
Resveratrol reduces TNFα, IL-1β, IL-6, COX-2 gene expression in differentiated adipocytesFigure 8
Resveratrol reduces TNFα, IL-1β, IL-6, COX-2 gene expression in differentiated adipocytes. Experimental 
method for Fig. 8 was identical to that described for Fig. 7 except that resveratrol was substituted for curcumin.Page 10 of 13
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inhibit insulin receptor substrate -1 (IRS-1) expression
[60] and activation [61] thereby inducing insulin resist-
ance. By repressing IL-1β transcription during adipocyte
differentiation, insulin responsiveness can be maintained
for proper glucose homeostasis. Furthermore, because
expansion of adipose tissue is accompanied by accelerated
macrophage infiltration providing a substantial source of
secreted TNFα, which we show can activate IL-1β gene
expression, additional levels of regulation become neces-
sary to prevent secretion of IL-1β protein by adipocytes.
Collectively, these observations indicate that multiple reg-
ulatory checkpoints are in place to prevent IL-1β expres-
sion and ensure proper insulin responsiveness by
adipocytes.
In contrast to the results obtained for measurements of
secreted TNFα and IL-1β, TNFα-stimulation of adipocytes
did have a pronounced effect on secreted levels of IL-6 and
PGE2. We found little or no IL-6 secreted by unstimulated,
fully differentiated adipocytes; however, when stimulated
with TNFα, a significant level of secreted IL-6 was meas-
ured. In spite of a lack of secreted IL-6, we found that the
IL-6 gene is expressed in unstimulated adipocytes and is
responsive to TNFα stimulation as mRNA levels increased
by 6-fold. These data indicate that TNFα stimulation of
adipocytes not only increases transcriptional activity of
the IL-6 gene, but also activates post-transcriptional
events to produce secreted IL-6. Secreted PGE2 levels were
also measured as a direct assessment of COX-2 activity.
We found that TNFα-stimulation modestly increased
COX-2 gene expression by 2-fold and increased secreted
PGE2 by 3-fold over basal levels found in unstimulated
adipocytes. Notably, both curcumin and resveratrol treat-
ment of TNFα-stimulated adipocytes significantly reduced
secreted levels of IL-6 and PGE2 in a dose-dependent man-
ner. IC50 values for curcumin and resveratrol inhibition of
IL-6 are estimated to be ~20 μM. By contrast, IC50 values
for inhibition of PGE2 differ for each compound; ~2 μM
for curcumin and > 20 μM for resveratrol. These IC50 val-
ues determined for secreted levels of IL-6 and PGE2 are
noticeably higher than what was measured for inhibition
of IL-6 and COX-2 gene expression. These differences are
most likely due to previously unidentified effects of curcu-
min and resveratrol on post-transcriptional events and
highlight the importance of measuring the final product
in addition to transcriptional levels when identifying the
quantitative effects of potential inhibitory compounds.
Whenever a compound is being developed as a potential
therapeutic, issues involving in vivo bioavailability must
be addressed. In this regard, data thus far presented on the
pharmacokinetics of curcumin [62,63] and resveratrol
[64] have been confusing and often times contradictory.
Curcumin and resveratrol reduce secreted PGE2 levels by TNFα-stimulated adipocytesFigure 10
Curcumin and resveratrol reduce secreted PGE2 lev-
els by TNFα-stimulated adipocytes. Experimental 
method for Fig. 10 was identical to that described for Fig. 9 
except that PGE2 levels in culture media were quantified by 
competitive binding ELISA. Student's t-test was performed to 
determine statistical probability (p).
Curcumin and resveratrol reduce secreted IL-6 levels by TNFα-stimulated adipocytesFigure 9
Curcumin and resveratrol reduce secreted IL-6 levels 
by TNFα-stimulated adipocytes. Adipocytes were incu-
bated without or with TNFα. In parallel, adipocytes were 
also co-incubated with TNFα and 2 or 20 μM curcumin or 
resveratrol as indicated. After 62 h incubation, secreted lev-
els of IL-6 were quantified by capture ELISA. Student's t-test 
was performed to determine statistical probability (p). N.D., 
none detected.Page 11 of 13
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they are rapidly metabolized to their glucuronide and sul-
fated forms. These metabolites, readily found in the circu-
lation, typically demonstrate very low cell permeability
and questionable bioactivity when compared to their
unmetabolized forms. In spite of these hurdles, the in vivo
efficacies of curcumin and resveratrol have been reproduc-
ibly shown by numerous investigators. Many challenges
lie ahead in order to systematically and quantitatively
address the pharmacokinetics of these natural products.
Immediate questions that need to be addressed to
improve on in vivo efficacy include, 1) do the metabolites
of curcumin and resveratrol have comparable bioactivity
with the parent compounds, 2) does the circulating pool
of metabolites represent a source of inhibitor that can be
modified to their more active forms, and 3) can chemical
substitutions be made to the base structures of curcumin
and resveratrol making them more active and less suscep-
tible to conjugation.
Most importantly for our hypothesis, the results presented
here provide proof-of-principle evidence that use of cur-
cumin and resveratrol represents a promising new thera-
peutic approach to reduce both local and systemic
inflammatory contributions by adipose tissue. At present,
we believe that the low μM IC50 values of curcumin and
resveratrol together with their positive in vivo effects make
these natural products excellent lead compounds to guide
the development of more potent inhibitors of NF-κB acti-
vation and inflammatory gene expression. Toward this
goal, we have recently developed chemical libraries of
synthetic analogs based on the chemical structures of cur-
cumin [23] and resveratrol [22]. Studies are currently
underway to identify if these novel structural analogs
improve upon the inhibitory properties of the parent
compounds while also critically addressing the challenges
of bioavailability and in vivo metabolism.
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